- In recognition of World Diabetes Day, Roche and Mark Cuban Cost Plus Drug Company announce a new partnership to provide affordable access to supplies needed for testing blood glucose.
- The Accu-Chek® blood glucose monitoring system will be the first branded product and the first medical device offered on costplusdrugs.com.
- Roche and Mark Cuban Cost Plus Drug Company are committed to more equitable care for the 37 million Americans living with diabetes.
Indianapolis, November 14, 2022 - - Roche today announced a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to provide affordable access to the Accu-Chek® blood glucose monitoring system used by people with diabetes to test their blood sugar. Improving access to diabetes care remains a critical issue among the diabetes community and is the theme for World Diabetes Day 2021 – 2023.
The Accu-Chek® Guide Me meter, Softclix lancing device, Softclix lancets and Accu-Chek Guide test strips, all manufactured by Roche Diabetes Care, an innovator in diabetes care for over 40 years, will be the first branded products and the first medical devices offered on costplusdrugs.com. Additionally, access to the mySugr diabetes management app, relied on by over 4 million users worldwide, will be available with the Accu-Chek Guide Me meter.
“People living with diabetes, the most expensive chronic disease in the nation, should not be forced to decide between managing their disease or feeding their families,” said Matt Jewett, Senior Vice President and General Manager, Roche Diabetes Care. “This collaboration with Mark Cuban Cost Plus Drug Company will expand access to high-quality, potentially lifesaving diabetes care supplies for those who need them most, a shared commitment of both our organizations and the diabetes community.”
Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drugs said, "We will do whatever it takes to get affordable pharmaceuticals and products to help patients improve their care. We are excited to advance health equity for people with diabetes with Roche by our side.”
Millions of Americans are facing hard decisions when it comes to medical care. An estimated 98 million adults have to take extraordinary steps to afford healthcare, according to a new Gallup study.1 Further, a recent CDC report revealed over 31 million Americans had no healthcare insurance in 2020.2
Cost Plus Drugs entered the direct-to-consumer marketplace in January 2022 with a pledge to be “radically transparent” in negotiations with drug and device companies and has already developed partnerships with generic manufacturers. The collaboration with Roche is the first of what Cost Plus Drugs believes will be many to come in brand manufacturer offerings.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments for better outcomes and true relief.
Since 2017, mySugr, one of the most popular diabetes management apps, has been part of Roche Diabetes Care.
For more information, please visit www.accu-chek.com and www.rochediabetes.com.
All trademarks used or mentioned in this release are protected by law.
 CDC National Health Statistics Report, Feb 2022 https://www.cdc.gov/nchs/data/nhsr/nhsr169.pdf.
For further information, please contact:
Amy Lynn ([email protected])